-

03:52:46 AM

BVXV Stock News

BVXV - Biondvax Pharmaceuticals Ltd

06/05/23 7:00 AM

Nasdaq : BVXV

low float

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis. BiondVax to lead development and commercialization of NanoAbs with

RHEA-AI

positive

05/15/23 4:45 PM

Nasdaq : BVXV

earningslow float

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today

RHEA-AI

neutral

04/20/23 5:45 AM

Nasdaq : BVXV

covid-19low float

United States Influenza Vaccines Market Analysis Report 2023: COVID-19/Influenza Combination Vaccines Gaining Momentum with GSK, CureVac and Novavax's Continued Advancements

The influenza vaccines market in the United States was valued at US$ 3,962 million in 2022 and is expected to reach US$ 8,347 million by 2031, registering a CAGR of 8.6% during the forecast period. This report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size,...

RHEA-AI

neutral

04/17/23 4:25 PM

Nasdaq : BVXV

low float

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune

RHEA-AI

positive

03/16/23 1:10 PM

Nasdaq : BVXV

conferenceslow float

BiondVax to Present at BIO-Europe Spring

via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune

RHEA-AI

neutral

02/02/23 2:15 PM

Nasdaq : BVXV

low float

BiondVax Presenting at BIO CEO & Investor Conference

via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune

RHEA-AI

very positive

01/23/23 6:25 AM

Nasdaq : BVXV

low float

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data indicated NanoAb

RHEA-AI

neutral

01/06/23 7:15 AM

Nasdaq : BVXV

covid-19low float

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placebo Result builds on recently announced data indicating NanoAb treatment led to

RHEA-AI

neutral

01/05/23 7:00 AM

Nasdaq : BVXV

conferenceslow float

BiondVax to Present at Biotech Showcase 2023

via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases,

RHEA-AI

very positive

12/30/22 7:30 AM

Nasdaq : BVXV

low float

BiondVax CEO Issues Letter to Shareholders

via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today

RHEA-AI

positive

1 2 3 4 5 6 7 Next

BVXV Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.biondvax.com
CeoRon Babecoff
Security nameBiondvax Pharmaceuticals Ltd - ADR
Issue typead
SectorManufacturing
Sic code2836
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressWeizmann Science Park
StateNess Ziona
CityPo Box 4143 14 Einstein Street
Zip7403618
CountryIsrael
Phone97289302529

About Biondvax Pharmaceuticals Ltd

BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M 001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M 001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.